Clinical advancements in psychedelic-based treatments are accelerating notably. Beckley Psytech’s intranasal mebufotenin demonstrated significant symptom reductions in treatment-resistant depression during a Phase 2b trial, meeting primary endpoints and triggering a merger with Atai Life Sciences. Investor enthusiasm is rising in this emerging therapeutic class, bolstered by regulatory openness and supportive health policy leadership. These developments underscore psychedelics’ growing role in psychiatric medicine.